South Korea-based Alteogen has signed an exclusive licensing deal worth up to $365m with a global pharmaceutical company, granting worldwide rights to develop and commercialise a subcutaneous biologic product using its Hybrozyme technology.
The application passed the preliminary examination of the PRC State Intellectual Property Bureau and was accepted for review; the application acceptance number is 201410182757.7. The filed patent is
Founded in 2003, HMT is a global leader in the emerging fields of metabolomics and systems biology. HMT will apply their proprietary, state-of-the-art capillary electrophoresis-mass spectrometry (CE-MS) technologies
The study will be conducted by way of a biOasis grant to the Brains for Brain Foundation ("B4B") of Padova, Italy, headed by renowned Lysosomal Storage Disease expert,
The all- natural, high performance products were developed together with Hard Core Beverages in Australia and Private Label Nutraceuticals in Georgia. The new formula is both gluten —
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.
